aptevotherapeutics.com (APVO) - Long-Term Debt to Capital Coefficient

Aptevo Therapeutics brings together leading antibody scientists to combat cancer, providing them with an environment for breakthrough discoveries in immunotherapy. The business relies on the ADAPT system, where unique developments are patent-protected and monetized through B2B licenses. The current metric stands at 0.54. This price chart illustrating trading dynamics complements data on the company, which independently conducts clinical trials, avoids mergers, and limits partnerships to supply agreements.

Assessing the financial stability of Aptevo Therapeutics (APVO) requires an analysis of its long-term liability structure. This ratio compares loans with a maturity of over one year against total equity, determining the business's degree of dependence on external financing. By analyzing the trend of long-term debt to equity, an investor can identify the risk of inflationary depreciation. A low debt load allows the company to effectively scale sales of hemophilia medications, while a high gross margin facilitates rapid profit growth.